Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736485 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL5029670 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL182764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4391706 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1814559-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006045050-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-04-27 | — | — | WO | claimed |
| EP-4349902-A1 | RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349900-A1 | VULCANIZED RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349901-A1 | RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024005029-A1 | VULCANIZED RUBBER COMPOSITION FOR TIRES, AND TIRE | 株式会社ブリヂストン | 2024-01-04 | — | — | WO | disclosed |
| WO-2023243129-A1 | RUBBER COMPOSITION FOR TIRE, AND TIRE | 株式会社ブリヂストン | 2023-12-21 | — | — | WO | disclosed |
| US-20230040071-A1 | RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2023-02-09 | — | — | US | disclosed |
| WO-2022254750-A1 | RUBBER COMPOSITION AND TIRE | 株式会社ブリヂストン | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254751-A1 | RUBBER COMPOSITION AND TIRE | 株式会社ブリヂストン | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254749-A1 | VULCANIZED RUBBER COMPOSITION AND TIRE | 株式会社ブリヂストン | 2022-12-08 | — | — | WO | disclosed |
| WO-2021124811-A1 | RUBBER COMPOSITION AND TIRE | 株式会社ブリヂストン | 2021-06-24 | — | — | WO | disclosed |
| EP-3495162-A1 | PNEUMATIC TIRE | Sumitomo Rubber Industries, Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| CN-103124739-B | A kind of new glucagon-like peptide-1 analogs, composition and use thereof | BETTA PHARMACEUTICALS Co.,Ltd. (CN) | 2015-11-25 | — | — | CN | disclosed |
| EP-2514407-A1 | Stable non-aqueous pharmaceutical compositions | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1814559-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006045050-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | GZMB, RNASE1, CASP3 | GBA1 722/4885SLC2A1 2310/4885MAPK1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.